Skip to main content

Advertisement

SpringerLink
Log in

The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?

  • Clinical Implications
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. http://seer.cancer.gov

  2. http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf

  3. Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146–8151

    Article  PubMed  Google Scholar 

  4. Schroder FH, Gosselaar C, Roemeling S, Postma R, Roobol MJ, Bangma C (2006) PSA and the detection of prostate cancer after 2005. Part 1. EAU-EBU update series. Eur Urol 4:2–12

    Google Scholar 

  5. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239–2246

    Article  PubMed  CAS  Google Scholar 

  6. Carroll PR (2005) Early stage prostate cancer—do we have a problem with over-detection, overtreatment or both? J Urol 173:1061–1062

    Article  PubMed  Google Scholar 

  7. Gonzalgo ML, Isaacs WB (2003) Molecular pathways to prostate cancer. J Urol 170:2444–2452

    Article  PubMed  CAS  Google Scholar 

  8. Li LC, Carroll PR, Dahiya R (2005) Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97:103–115

    Article  PubMed  CAS  Google Scholar 

  9. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC (2005) Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23:2903–2910

    Article  PubMed  CAS  Google Scholar 

  10. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C (2006) Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumour development in prostate cancer. J Mol Med (in press). DOI 10.1007/s109-006-0099-4

  11. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808–811

    PubMed  CAS  Google Scholar 

  12. Dhawan D, Hamdy FC, Patterson J, Rehman I, Feeley K, Meuth M, Catto JWF (2006) Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 209:336–343

    Article  PubMed  CAS  Google Scholar 

  13. Padar A, Sathyanarayana UG, Suzuki M, Maruyama R, Hsieh JT, Frenkel EP, Minna JD, Gazdar AF (2003) Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res 9:4730–4734

    PubMed  CAS  Google Scholar 

  14. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW (2006) Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 25:1984–1988

    Article  PubMed  CAS  Google Scholar 

  15. Harden SV, Guo Z, Epstein JI, Sidransky D (2003) Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 169:1138–1142

    Article  PubMed  CAS  Google Scholar 

  16. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–1266

    Article  PubMed  CAS  Google Scholar 

  17. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11:8321–8325

    Article  PubMed  CAS  Google Scholar 

  18. Catto JW, Abbod MF, Linkens DA, Hamdy FC (2006) Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression. J Urol 175:474–479

    Article  PubMed  Google Scholar 

  19. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11:4037–4043

    Article  PubMed  CAS  Google Scholar 

  20. Fronsdal K, Saatcioglu F (2005) Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. J Hered 62:299–306

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinician Scientist and Senior Lecturer, Academic Urology Unit, K Floor, Royal Hallamshire Hospital, Glossop road, S10 2JF, Sheffield, UK

    James W. F. Catto

Authors
  1. James W. F. Catto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James W. F. Catto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Catto, J.W.F. The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?. J Mol Med 84, 883–885 (2006). https://doi.org/10.1007/s00109-006-0110-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-006-0110-0

Search

Navigation